Posted by Michael Wonder on 23 Aug 2019
NICE to work with company on addressing issues in appraisals of cannabidiol for treating difficult to control epilepsies
23 August 2019 - NICE has today announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.
NICE’s draft guidance, also published today, does not recommend the drug (also called Epidyolex and made by GW Pharma), used with clobazam, for treating Dravet and Lennox-Gastaut syndromes, types of epilepsy which begin in early childhood and which are lifelong and difficult to control.
